EyePoint Pharmaceuticals, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) develops and commercializes innovative therapeutics for serious retinal diseases using its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery; its lead product candidate DURAVYU (EYP-1901) combines vorolanib, a selective tyrosine kinase inhibitor, for VEGF-mediated conditions including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), with prior Durasert formulations supporting four FDA-approved products administered to thousands of patients. Founded in 1987 and headquartered in Watertown, Massachusetts, with a manufacturing facility in Northbridge, Massachusetts, the clinical-stage biopharmaceutical company targets ophthalmology markets in the US and globally through Phase 3 pivotal trials. Recently, EyePoint completed enrollment in the Phase 3 LUGANO and LUCIA trials for DURAVYU in wet AMD involving over 900 patients, with topline data from LUGANO expected mid-2026; initiated the pivotal Phase 3 DME program with COMO and CAPRI trials following FDA alignment on a non-inferiority pathway, first dosing anticipated Q1 2026; presented preclinical data at AAO 2025 showing DURAVYU reduces IL-6 mediated inflammation by over 50% via JAK-1 inhibition alongside VEGF blockade; and raised $172.5 million in an oversubscribed October 2025 public offering to fund the DME program and extend cash runway into Q4 2027.
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears
EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
EyePoint: DURAVYU's Durability Could Drive Significant Upside
EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Ramiro Ribeiro Sells 2,437 Shares of Stock
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT
EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Analysts
EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema